Drugs that, in some reports, have been weakly associated with Torsades de Pointes and/or QT prolongation but that are unlikely to be a risk for Torsades de Pointes when used in usual recommended dosages and in patients without other risk factors (e.g., concomitant QT prolonging drugs, bradycardia, electrolyte disturbances, congenital long QT syndrome, concomitant drugs that inhibit metabolism).
 
 
Amitriptyline Elavil® Tricyclic Antidepressant / depression
Amoxapine Asendin® Tricyclic Antidepressant / depression
Ciprofloxacin Cipro® Antibiotic / bacterial infection
Citalopram Celexa® Anti-depressant / depression
Clomipramine Anafranil® Tricyclic Antidepressant / depression
Desipramine Pertofrane® Tricyclic Antidepressant / depression
Doxepin Sinequan® Tricyclic Antidepressant / depression
Fluconazole Diflucan® Anti-fungal / fungal infection
Fluoxetine Prozac® Anti-depressant / depression
Fluoxetine Sarafem® Anti-depressant / depression
Galantamine Reminyl® Cholinesterase inhibitor / Dementia, Alzheimer's
Imipramine Norfranil® Tricyclic Antidepressant / depression
Itraconazole Sporanox® Anti-fungal / fungal infection
Ketoconazole Nizoral® Anti-fungal / fungal infection
Mexiletine Mexitil® Anti-arrhythmic / Abnormal heart rhythm
Nortriptyline Pamelor® Tricyclic Antidepressant / depression
Paroxetine Paxil® Anti-depressant / depression
Protriptyline Vivactil® Tricyclic Antidepressant / depression
Sertraline Zoloft® Anti-depressant / depression
Solifenacin VESIcare® muscarinic receptor anatagonist / treatment of overactive bladder
Trimethoprim-Sulfa Bactrim® Antibiotic / bacterial infection
Trimethoprim-Sulfa Sulfa® Antibiotic / bacterial infection
Trimipramine Surmontil® Tricyclic Antidepressant / depression
 
 
Revised: 12/17/2004

Source:www.torsades.org
Close Window
     

Arizona Center for Education and Research on Therapeutics
The Critical Path Institute

Tucson, Arizona and Rockville, Maryland

Funded in part by Agency for Healthcare Research and Quality grant 1 U18 HS10385-01

Disclaimer and Waiver
The information presented is intended solely for the purpose of providing general information about health related matters. It is not intended for any other purpose, including, but not limited to, medical or pharmaceutical advice and/or treatment, nor is it intended to substitute for the users' relationships with their own health care/pharmaceutical providers. To that extent, by continued use of this program, the user affirms the understanding of the purpose and releases The Critical Path Institute, The University of Arizona, State of Arizona and Arizona Board of Regents from any claims arising out of his/her use of the website.

 

Risk Group 2 Risk Group 3 Risk Group 1 Risk Group 1 Drug List 2 Risk Group 4